CULLINAN THERAPEUTICS, INC. Net Income (Loss), Including Portion Attributable to Noncontrolling Interest
CULLINAN THERAPEUTICS, INC. (CGEM) reported Net Income (Loss), Including Portion Attributable to Noncontrolling Interest of -$53.70 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Net Income
us-gaap:ProfitLoss · last filed 2026-08-06
- CULLINAN THERAPEUTICS, INC. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2026-06-30 was -$53.70M.
- CULLINAN THERAPEUTICS, INC. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2026-03-31 was -$49.66M.
- CULLINAN THERAPEUTICS, INC. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2025-12-31 was -$50.71M.
- CULLINAN THERAPEUTICS, INC. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2025-09-30 was -$50.61M.
- CULLINAN THERAPEUTICS, INC. net income (loss), including portion attributable to noncontrolling interest for fiscal 2025 was -$219.88M.
- CULLINAN THERAPEUTICS, INC. net income (loss), including portion attributable to noncontrolling interest for fiscal 2024 was -$167.57M.
- CULLINAN THERAPEUTICS, INC. net income (loss), including portion attributable to noncontrolling interest for fiscal 2023 was -$155.10M, a 242.04% decline from fiscal 2022.
- CULLINAN THERAPEUTICS, INC. net income (loss), including portion attributable to noncontrolling interest for fiscal 2022 was $109.19M.
| Period end | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 3 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 6 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 9 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$53.70M 10-Q · filed 2026-08-06 | -$103.36M 10-Q · filed 2026-08-06 | -$154.08M derived: sum of 3 quarters · filed 2026-08-06 | -$204.69M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$49.66M 10-Q · filed 2026-08-06 | -$100.37M derived: sum of 2 quarters · filed 2026-08-06 | -$150.98M derived: sum of 3 quarters · filed 2026-08-06 | -$221.04M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$50.71M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | -$101.32M derived: sum of 2 quarters · filed 2026-03-10 | -$171.38M derived: sum of 3 quarters · filed 2026-08-06 | -$219.88M 10-K · filed 2026-03-10 |
| 2025-09-30 | -$50.61M 10-Q · filed 2025-11-06 | -$120.67M derived: sum of 2 quarters · filed 2026-08-06 | -$169.17M 10-Q · filed 2025-11-06 | -$216.81M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$70.06M 10-Q · filed 2026-08-06 | -$118.56M 10-Q · filed 2026-08-06 | -$166.20M derived: sum of 3 quarters · filed 2026-08-06 | -$206.76M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$48.50M 10-Q · filed 2026-08-06 | -$96.15M derived: sum of 2 quarters · filed 2026-08-06 | -$136.71M derived: sum of 3 quarters · filed 2026-08-06 | -$178.74M derived: sum of 4 quarters · filed 2026-08-06 |
| 2024-12-31 | -$47.65M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | -$88.21M derived: sum of 2 quarters · filed 2026-03-10 | -$130.24M derived: sum of 3 quarters · filed 2026-03-10 | -$167.57M 10-K · filed 2026-03-10 |
| 2024-09-30 | -$40.56M 10-Q · filed 2025-11-06 | -$82.59M derived: sum of 2 quarters · filed 2025-11-06 | -$119.93M 10-Q · filed 2025-11-06 | -$145.49M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | -$42.03M 10-Q · filed 2025-11-06 | -$79.37M 10-Q · filed 2025-08-07 | -$104.93M derived: sum of 3 quarters · filed 2025-11-06 | -$144.11M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-03-31 | -$37.34M 10-Q · filed 2025-11-06 | -$62.90M derived: sum of 2 quarters · filed 2025-11-06 | -$102.09M derived: sum of 3 quarters · filed 2025-11-06 | -$134.30M derived: sum of 4 quarters · filed 2025-11-06 |
| 2023-12-31 | -$25.56M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$64.75M derived: sum of 2 quarters · filed 2025-02-27 | -$96.96M derived: sum of 3 quarters · filed 2025-02-27 | -$155.10M 10-K · filed 2025-02-27 |
| 2023-09-30 | -$39.18M 10-Q · filed 2024-11-07 | -$71.40M derived: sum of 2 quarters · filed 2024-11-07 | -$129.54M 10-Q · filed 2024-11-07 | -$156.63M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | -$32.21M 10-Q · filed 2024-11-07 | -$90.36M 10-Q · filed 2024-08-08 | -$117.44M derived: sum of 3 quarters · filed 2024-11-07 | -$142.33M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-03-31 | -$58.14M 10-Q · filed 2024-11-07 | -$85.23M derived: sum of 2 quarters · filed 2024-11-07 | -$110.12M derived: sum of 3 quarters · filed 2024-11-07 | $63.95M derived: sum of 4 quarters · filed 2024-11-07 |
| 2022-12-31 | -$27.09M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | -$51.98M derived: sum of 2 quarters · filed 2024-03-14 | $122.09M derived: sum of 3 quarters · filed 2024-03-14 | $109.19M 10-K · filed 2024-03-14 |
| 2022-09-30 | -$24.89M 10-Q · filed 2023-11-08 | $149.18M derived: sum of 2 quarters · filed 2023-11-08 | $136.28M 10-Q · filed 2023-11-08 | $102.08M derived: sum of 4 quarters · filed 2023-11-08 |
| 2022-06-30 | $174.06M 10-Q · filed 2023-11-08 | $161.17M 10-Q · filed 2023-08-10 | $126.97M derived: sum of 3 quarters · filed 2023-11-08 | $108.71M derived: sum of 4 quarters · filed 2023-11-08 |
| 2022-03-31 | -$12.89M 10-Q · filed 2023-11-08 | -$47.10M derived: sum of 2 quarters · filed 2023-11-08 | -$65.36M derived: sum of 3 quarters · filed 2023-11-08 | -$81.80M derived: sum of 4 quarters · filed 2023-11-08 |
| 2021-12-31 | -$34.21M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | -$52.47M derived: sum of 2 quarters · filed 2023-03-09 | -$68.90M derived: sum of 3 quarters · filed 2023-03-09 | -$67.48M 10-K · filed 2023-03-09 |
| 2021-09-30 | -$18.26M 10-Q · filed 2022-11-14 | -$34.70M derived: sum of 2 quarters · filed 2022-11-14 | -$33.28M 10-Q · filed 2022-11-14 | -$62.38M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | -$16.44M 10-Q · filed 2022-11-14 | -$15.02M 10-Q · filed 2022-08-10 | -$44.13M derived: sum of 3 quarters · filed 2022-11-14 | -$55.44M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-03-31 | $1.42M 10-Q · filed 2022-11-14 | -$27.69M derived: sum of 2 quarters · filed 2022-11-14 | -$39.00M derived: sum of 3 quarters · filed 2022-11-14 | -$52.88M derived: sum of 4 quarters · filed 2022-11-14 |
| 2020-12-31 | -$29.11M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | -$40.42M derived: sum of 2 quarters · filed 2022-03-17 | -$54.30M derived: sum of 3 quarters · filed 2022-03-17 | -$59.46M 10-K · filed 2022-03-17 |
| 2020-09-30 | -$11.31M 10-Q · filed 2021-11-09 | -$25.19M derived: sum of 2 quarters · filed 2021-11-09 | -$30.35M 10-Q · filed 2021-11-09 | |
| 2020-06-30 | -$13.88M 10-Q · filed 2021-11-09 | -$19.04M 10-Q · filed 2021-08-10 | ||
| 2020-03-31 | -$5.16M 10-Q · filed 2021-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |